Vertex Pharmaceuticals Incorporated

🇺🇸NASDAQ Global Select
Back to all articles
Vertex Pharmaceuticals Incorporated stock analysis VRTX overview
Somewhat Bearish -25

Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

📉 Vertex Pharmaceuticals Inc. (VRTX) shares slipped 1.60% to $423.24 on Wednesday, following an overall weak trading session for the broader market.

📊 The S&P 500 Index fell 0.04% to 7,135.95, while the Dow Jones Industrial Average dropped 0.57% to 48,861.81 during the same period.

📈 VRTX closed 17.14% below its 52-week high of $510.77, which the stock had reached on April 30th.

⚠️ The company's underperformance was noted against its competitors during this Wednesday trading session.

Risk Factors
  • Vertex Pharmaceuticals Inc. stock slipped 1.60% to $423.24 on a poor trading session, underperforming against the broader market.
  • The shares remain closed 17.14% below its 52-week high of $510.77, which was reached on April 30th.
Full Analysis
Vertex Pharmaceuticals Inc. (VRTX) shares closed lower on Wednesday, slipping 1.60% to $423.24 as the broader market experienced a downturn. The S&P 500 Index fell 0.04% to close at 7,135.95, while the Dow Jones Industrial Average dropped 0.57% to 48,861.81 during the trading session. Despite this dip, VRTX remains significantly below its recent peak; the stock closed 17.14% short of its 52-week high of $510.77, which was reached on April 30th. The decline in Vertex Pharmaceuticals stock occurred within an all-around poor trading session for the overall stock market. MarketWatch reported the data alongside information from Dow Jones and FactSet to track performance metrics. All quotes presented reflect local exchange time, and intraday data provided by FACTSET includes a delay of at least 15 minutes or per exchange requirements, based on trades reported through Nasdaq for U.S. stock quotes. The article notes that MarketWatch Automation partners with Automated Insights to deliver pertinent content at record speed using world-class market data. The publication, dated April 29, 2026, holds all rights reserved under its copyright policy. While the specific reasons for VRTX's underperformance relative to competitors are not detailed in the provided text beyond general market weakness, the share price action highlights a gap between current trading levels and the recent high established just days prior.